Cover Image
市場調查報告書

熱門市場分析:亨丁頓舞蹈症

Market Spotlight: Huntington's Disease

出版商 Datamonitor Healthcare 商品編碼 573554
出版日期 內容資訊 英文 30 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
熱門市場分析:亨丁頓舞蹈症 Market Spotlight: Huntington's Disease
出版日期: 2018年01月18日 內容資訊: 英文 30 Pages
簡介

全球30歲以上人口的亨丁頓舞蹈症患病人數,預測將從2016年的155,620人,到2025年增加到181,760人。盛行率是北美最大 (0.0073%),亞洲最小 (0.0004%) 。

本報告提供全球亨丁頓舞蹈症的市場調查,提供疾病的背景·概要,患病人數的十年預測,開發平台藥物及已上市藥物概要,臨床試驗狀況,授權·資產收購等主要交易趨勢,並彙整專利資訊,主要藥物的收益預測等資料。

要點

疾病的背景

  • 亨丁頓舞蹈症的亞型

治療

  • 舞蹈病的治療
  • 帕金森氏症的治療
  • 行動功能障礙·精神疾病的治療

流行病學

開發平台藥物

已上市藥物

  • 核准:各國

近未來的主要趨勢

主要的法規趨勢

  • FDA的Austedo的認證

授權·資產收購等的交易

母專利

商機

臨床試驗環境

  • 贊助商:status別
  • 贊助商:不同階段

文獻

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC0178508

This Market Spotlight report covers the Huntington's disease market, comprising key pipeline and marketed drugs, clinical trials, upcoming and regulatory events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways

  • Datamonitor Healthcare estimates that in 2016 there were 155,620 prevalent cases of Huntington's disease in adults aged 30 years and older worldwide, and forecasts that number to increase to 181,760 prevalent cases by 2025.
  • Northern America is estimated to have the largest prevalence proportion (0.0073%) while Asia has the smallest prevalence proportion (0.0004%).
  • A majority of industry-sponsored drugs in active clinical development for Huntington's disease are in Phase II. Therapies in mid and late-stage development for Huntington's disease focus on a wide variety of targets. Among these therapies, Procysbi, an enteric-coated micro-bead formulation of cysteamine bitartrate, is closest to market. The majority of the pipeline drugs in mid-to-late-stage development for Huntington's disease are administered via the oral route.
  • Valeant Pharmaceuticals' Xenazine and Teva Pharmaceutical's Austedo, which target vesicular monamine transporters, are the only marketed drugs for Huntington's disease. The drugs are administered via the oral route. Austedo, a deuteriumsubstituted analogue of tetrabenazine, was approved by the US Food and Drug Administration (FDA) in April 2017.
  • The topline Phase II trial results for IONIS-HTTRx, VX15, and Nerventra are the high-impact upcoming events in the Huntington's disease space.
  • There were eight licensing and asset acquisition activities involving Huntington's disease drugs during 2013-18, three of which occurred in 2015.
  • The exclusive licensing agreement in 2015 between Neurocrine Biosciences and Mitsubishi Tanabe Pharma to develop and commercialize Neurocrine Biosciences' VMAT2 inhibitor - NBI-98854 - in Japan and certain selected Asian markets, for $115m, was the largest deal during the period.
  • The clinical trials distribution across Phase I-IV indicates that the majority of trials for Huntington's disease have been in early and mid phases of development, with 72.4% of trials in Phase I-II, and only 27.6% in Phase III-IV.
  • The US has a substantial lead in the number of Huntington's disease clinical trials globally. Germany and the UK lead the major EU markets.
  • Clinical trial activity in the Huntington's disease space is dominated by completed trials. Pfizer has the highest number of completed trials for Huntington's disease, with 12 completed trials.
  • Pfizer leads industry sponsors with the highest number of clinical trials for Huntington's disease, followed by Teva and NeuroSearch.

TABLE OF CONTENTS

KEY TAKEAWAYS

DISEASE BACKGROUND

  • Huntington's disease subtypes

TREATMENT

  • Treatment of chorea
  • Treatment of parkinsonism
  • Treatment of behavioral and psychiatric dysfunction

EPIDEMIOLOGY

MARKETED DRUGS

  • Approvals by country

PIPELINE DRUGS

KEY UPCOMING EVENTS

KEY REGULATORY EVENTS

  • FDA Approved Austedo

LICENSING AND ASSET ACQUISITION DEALS

PARENT PATENTS

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase

BIBLIOGRAPHY

  • Prescription information

APPENDIX

LIST OF FIGURES

  • Figure 1: Trends in prevalent cases of Huntington's disease, 2016-25
  • Figure 2: Pipeline drugs for Huntington's disease in the US
  • Figure 3: Pipeline drugs for Huntington's disease, by company
  • Figure 4: Pipeline drugs for Huntington's disease, by drug type
  • Figure 5: Pipeline drugs for Huntington's disease, by classification
  • Figure 6: Key upcoming events in Huntington's disease
  • Figure 7: Licensing and asset acquisition deals in Huntington's disease
  • Figure 8: Parent patents in Huntington's disease
  • Figure 9: Clinical trials in Huntington's disease
  • Figure 10: Top 10 drugs for clinical trials in Huntington's disease
  • Figure 11: Top 10 companies for clinical trials in Huntington's disease
  • Figure 12: Trial locations in Huntington's disease
  • Figure 13: Huntington's disease trials status
  • Figure 14: Huntington's disease trials sponsors, by phase

LIST OF TABLES

  • Table 1: Prevalent cases of Huntington's disease, 2016-25
  • Table 2: Prevalence proportions of Huntington's disease, 2016-25
  • Table 3: Marketed drugs for Huntington's disease
  • Table 4: Approvals by country for Huntington's disease
  • Table 5: Pipeline drugs for Huntington's disease in the US
  • Table 6: Historical global sales, by drug ($m), 2012-16
  • Table 7: Forecasted global sales, by drug ($m), 2017-22
Back to Top